Aptimmune Biologics inks $2.75 mln
Champaign, Illinois-based mucosal vaccine company Aptimmune Biologics has secured $2.75 million in funding. The investors included Arsenal Capital Management and Fox Ventures LLC.
9 July 2015•2 mins read
Champaign, Illinois-based mucosal vaccine company Aptimmune Biologics has secured $2.75 million in funding. The investors included Arsenal Capital Management and Fox Ventures LLC.
